Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Octreotide acetate: Phase II data

In an open-label, 6-month, European Phase II trial, IDEV's octreotide implant maintained GH levels at <5

Read the full 160 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE